Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes
作者： C A Altar , J M Carhart , J D Allen , D K Hall-Flavin , B M Dechairo
DOI: 10.1038/TPJ.2014.85
关键词:
摘要: … variations in genes for four cytochrome P450 (CYP) enzymes (CYP2D6, CYP2C19, CYP2C9 and CYP1A2), the serotonin transporter (SLC6A4) and serotonin 2A receptor (HTR2A) with …
elsevier.com
nature.com
biostatshed.com 参考文章(29)
Carhart Jm, Winner Jg, Allen Jd, Dechairo Bm, Altar Ca, A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discovery Medicine. ,vol. 16, pp. 219- ,(2013)
Julio Licinio, Ma-Li Wong, Pharmacogenomics of antidepressant treatment effects. Dialogues in clinical neuroscience. ,vol. 13, pp. 63- 71 ,(2011)
Daowen Zhang, Xihong Lin, Variance Component Testing in Generalized Linear Mixed Models for Longitudinal/Clustered Data and other Related Topics Springer, New York, NY. pp. 19- 36 ,(2008) , 10.1007/978-0-387-76721-5_2
C. Anthony Altar, John Hornberger, Ashwini Shewade, Victor Cruz, Jill Garrison, David Mrazek, Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy International Review of Psychiatry. ,vol. 25, pp. 509- 533 ,(2013) , 10.3109/09540261.2013.825579
Howard G. Birnbaum, Ronald C. Kessler, David Kelley, Rym Ben-Hamadi, Vijay N. Joish, Paul E. Greenberg, Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance Depression and Anxiety. ,vol. 27, pp. 78- 89 ,(2010) , 10.1002/DA.20580
Louise Herbild, Stig E. Andersen, Thomas Werge, Henrik B. Rasmussen, Gesche Jürgens, Does Pharmacogenetic Testing for CYP450 2D6 and 2C19 Among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Costs Basic & Clinical Pharmacology & Toxicology. ,vol. 113, pp. 266- 272 ,(2013) , 10.1111/BCPT.12093
Shu-Feng Zhou, Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clinical Pharmacokinectics. ,vol. 48, pp. 689- 723 ,(2009) , 10.2165/11318030-000000000-00000
J Jornil, Trine Skov Nielsen, I Rosendal, Johan Ahlner, Anna Lena Zackrisson, LWT Boel, B Brock, None, A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine Forensic Science International. ,vol. 226, ,(2013) , 10.1016/J.FORSCIINT.2012.12.020
A. John Rush, Ira H. Bernstein, Madhukar H. Trivedi, Thomas J. Carmody, Stephen Wisniewski, James C. Mundt, Kathy Shores-Wilson, Melanie M. Biggs, Ada Woo, Andrew A. Nierenberg, Maurizio Fava, An Evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: A Sequenced Treatment Alternatives to Relieve Depression Trial Report Biological Psychiatry. ,vol. 59, pp. 493- 501 ,(2006) , 10.1016/J.BIOPSYCH.2005.08.022
J Kirchheiner, K Nickchen, M Bauer, M-L Wong, J Licinio, I Roots, J Brockmöller, Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response Molecular Psychiatry. ,vol. 9, pp. 442- 473 ,(2004) , 10.1038/SJ.MP.4001494